Literature DB >> 20507307

MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3.

Michele Dal Bo, Paola Secchiero, Massimo Degan, Daniela Marconi, Riccardo Bomben, Gabriele Pozzato, Gianluca Gaidano, Giovanni Del Poeta, Francesco Forconi, Giorgio Zauli, Valter Gattei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20507307     DOI： 10.1111/j.1365-2141.2010.08185.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  16 in total

Review 1.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

Review 2.  RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Authors:  Stanley Lipkowitz; Allan M Weissman
Journal:  Nat Rev Cancer       Date:  2011-08-24       Impact factor: 60.716

Review 3.  The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.

Authors:  Vinod Pant; Alfonso Quintás-Cardama; Guillermina Lozano
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

4.  FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.

Authors:  Xiang Ling; Chao Xu; Chuandong Fan; Kai Zhong; Fengzhi Li; Xinjiang Wang
Journal:  Cancer Res       Date:  2014-12-15       Impact factor: 12.701

5.  The p53-MDM2/MDMX axis - A chemotype perspective.

Authors:  Kareem Khoury; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Medchemcomm       Date:  2011       Impact factor: 3.597

Review 6.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

8.  Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.

Authors:  Luis A Carvajal; Daniela Ben Neriah; Adrien Senecal; Lumie Benard; Victor Thiruthuvanathan; Tatyana Yatsenko; Swathi-Rao Narayanagari; Justin C Wheat; Tihomira I Todorova; Kelly Mitchell; Charles Kenworthy; Vincent Guerlavais; D Allen Annis; Boris Bartholdy; Britta Will; Jesus D Anampa; Ioannis Mantzaris; Manuel Aivado; Robert H Singer; Robert A Coleman; Amit Verma; Ulrich Steidl
Journal:  Sci Transl Med       Date:  2018-04-11       Impact factor: 17.956

Review 9.  Functions of MDMX in the modulation of the p53-response.

Authors:  Kristiaan Lenos; Aart G Jochemsen
Journal:  J Biomed Biotechnol       Date:  2011-03-22

Review 10.  Targeting p53 by small molecules in hematological malignancies.

Authors:  Manujendra N Saha; Lugui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2013-03-27       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.